 |
 |
A Therapeutic Step towards Health
Rhemacell 2G
Pharmacokinetics:
The oral form is released in the intestinal tract. Its main active ingredients are absorbed into the bloodstream by active transport through the chyliferous membranes. Between 20 and 60% of the dose administered is reabsorbed as biologically intact molecules, which are then distributed systemically, attaining their maximum concentration 6 hours later, and maintaining peak strength for 24 hours. The enzymes absorbed are metabolised hepatically and are eliminated through faecal and urinary excretion.
In the case of the injectable form, the active substances are absorbed quickly into the bloodstream. A significant part of the dosage, between 20 and 60% of the administered dose, is reabsorbed as biologically intact molecules; 4 to 6 hours later, maximum concentrations have been found in the plasma, which tend to last approximately 24 hours. After absorption, the enzymes are distributed systemically, acting especially at the site where a disease produced by deficiency of the same is located. This spot-targeting is based on the interaction with alpha-2 macroglobulin, a substance produced by activated immunological cells (macrophages/monocytes). The enzymes absorbed are eliminated at the level of the liver by other cells of the mononuclear phagocytic system, and ultimately through faecal and urinary excretion.
 |
||
More Information |
||
| » Rhemacell 2G » Clinical Information and Pharmacology » Mechanisms of Action » Pharmacokinetics |
» Indications » Contraindications » Toxicity » Clinical Studies |
» Conclusions
» Material and Methods » References |